Fortress Biotech (FBIO) vs Nomad Power Solutions (NMAD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nomad Power Solutions (NMAD) has outperformed Fortress Biotech (FBIO) over the past year, losing 11.2% versus a loss of 28.2%. Over five years, NMAD leads with a -77.2% price change compared with -95.5% for FBIO. Fortress Biotech is the larger company by market cap ($71.2 million vs $70.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | NMAD |
|---|---|---|
| Share price | $2.14 | $4.35 |
| Market cap | $71.24M | $70.04M |
| 1-day change | +2.20% | +1.87% |
| YTD return | -42.90% | +8.65% |
| 1-year return | -28.18% | -11.23% |
| 5-year return | -95.48% | -77.17% |
| P/E ratio (TTM) | 0.77 | — |
| EPS (TTM) | $2.76 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $8.38 |
| 52-week low | $2.00 | $2.36 |
| Distance from 52-week high | -52.85% | -48.09% |
| Analyst consensus | none | — |
| Avg. price target upside | +134.08% | — |
| Average volume | 495.05K | 273.42K |
| Shares outstanding | 33.35M | 16.10M |
| Employees | 78 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMAD has outperformed FBIO by 17.0 percentage points over the past year.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Health Care · Biotechnology: Pharmaceutical Preparations
FBIO vs NMAD FAQ
Which is bigger, Fortress Biotech or Nomad Power Solutions?
Fortress Biotech (FBIO) is larger, with a market capitalization of $71.24M compared with $70.04M for Nomad Power Solutions (NMAD).
Which stock has performed better over the past year, FBIO or NMAD?
NMAD returned -11.23% over the past 12 months, compared with -28.18% for FBIO (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and Nomad Power Solutions in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.